

# Introduction to MIAMOD/PIAMOD software

## Methods and instruments for estimating cancer incidence and prevalence from population-based data

*April 25-27, 2009*

*Cancer Institute Research Centre  
Tehran*

### 25 April, morning session

- 9,00     **Introduction** (*R. Capocaccia*)  
Welcome to participants. Motivation, aims and structure of the course
- 9,15     **Population-based estimates of cancer burden** (*R. De Angelis*)  
Definition and use of cancer burden indicators. Direct and indirect methods for estimating the epidemiological indicators. The transition rate method (MIAMOD/PIAMOD): use and applications.
- 9,45     **Population-based outcome indicators: cancer survival** (*R. Capocaccia*)  
Definitions and methods of computation
- 10,00    **Method overview – part I: basic equations and MIAMOD regression** (*R. Capocaccia*)  
Transition Rate equations relating morbidity and mortality probabilities  
Modelling cancer incidence with age-period-cohort (APC) models  
Modeling/extrapolating cancer survival: tabulated and model-based data  
MIAMOD solution to transition equations: regression on mortality data (back-calculation) to derive incidence parameters  
Basic outcomes (regression diagnostic statistics and morbidity estimates)
- 11,15    *Coffee break*
- 11,45    **Software overview – part I: the Graphical User Interface** (*R. De Angelis*)  
Overview of the software interface: main menu and flow to run a session
- 12,15    **Guided exercise 1** (*R. De Angelis*)  
Running a MIAMOD session.
- 13,00     *Lunch time*

## 25 April, afternoon session

- 14,00 **Method overview – part II: PIAMOD regression** (*R. Capocaccia*)  
PIAMOD solution to transition equations: regression on incidence data
- 14,30 **MIAMOD/PIAMOD Optional Outputs** (*R. De Angelis*)  
Prevalence estimates by disease duration and other optional outputs
- 15,00 **Guided exercise 2** (*R. De Angelis*)  
Running a PIAMOD session
- 15,15 **Exercise 1: Deriving default and optional outputs**  
Producing default and optional outputs by running the previously saved MIAMOD/PIAMOD sessions
- 16,15 Discussion on the results of Exercise 1
- 16,30 Conclusion

## 26 April , morning session

- 9,00 **Method overview – part III: Identification of the optimal incidence model** (*R. Capocaccia*)  
Improving incidence APC modelling: step-wise regression and cubic-splines
- 9,45 **Software overview– part II: regression with multiple models** (*R. De Angelis*)  
Session to execute multiple models  
Illustration of the step-wise procedure to find optimal incidence models
- 10,15 **Exercise 2: Performing a step-wise regression**  
Identification of the best model by using a PIAMOD multiple execution session
- 11,00 *Coffee break*
- 11, 30 **Model-based survival for MIAMOD/PIAMOD applications** (*R. De Angelis*)  
Role of survival in MIAMOD/PIAMOD estimates  
Survival models supported by MIAMOD/PIAMOD (mixture models with cure)  
Description of the SAS programs for modelling survival
- 12,30 **Using model-based survival in the Graphical User Interface** (*R. De Angelis*)  
Parameters setting and Plot utilities in the MIAMOD/PIAMOD software
- 13,00 *Lunch time*

## 26 April, afternoon session

14,00 **Time projections** (*R. De Angelis*)

Projections of incidence, survival and population. Projection scenarios with model-based survival.

14,30 **Exercise 3: Using model-based survival**

Evaluating the effect of different survival projection options on MIAMOD/PIAMOD estimates

15,30 **Discussion on the results of Exercise 3**

16,00 Conclusion

## 27 April, morning session

9,00 **MIAMOD/PIAMOD method: critical discussion** (*R. Capocaccia*)

Validation of the results and sensitivity analysis

Illustration of the main critical aspects

Application range and comparison with other methods

10,00 **International comparisons of cancer survival: the EURO CARE study** (*G. Gatta*)

Rationale, geographical coverage and main results of the EURO CARE-4 study

11,00 *Coffee break*

11,30 A presentation from hosting Institute on cancer epidemiology in Iran and on the Tehran Cancer Registry.

12,30 **Closing remarks and discussion**

13,00 Conclusion